IP Library › Granted Patent US 12661340
Granted Patent B2
US 12661340 · App. 18/656,222 · Granted Jun 23, 2026

Neuroprotective compositions and methods of using the same

Inventors: Jeffrey Erickson (New Orleans, LA); Heike Wulff (Davis, CA); Heesung Shim (Davis, CA); Vikrant Singh (Davis, CA); Latika Singh (Davis, CA)
Assignees: BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE; THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
A61K31/426A61K31/13A61K31/427A61K31/4439A61P25/28C07D277/40C07D401/12C07D417/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12661340
App. No.
18/656,222
Granted
Jun 23, 2026
Kind
B2
Abstract

This invention is directed to neuroprotective compositions and methods of using the same to treat neurodegenerative diseases.

Claims (11)

1 . A method for preventing, treating, and/or reducing the severity of a neurodegenerative disease in a subject, the method comprising administering to said subject in need thereof a therapeutically effective amount of the neuroprotective compound according to any one of the following structures:

a pharmaceutically acceptable salt thereof.

2 . The method of claim 1 , wherein the neurodegenerative diseases comprises Alzheimer's disease, global cerebral ischemia, amyotrophic lateral sclerosis, traumatic brain injury-induced epileptogenesis, peri-operative neuronal and/or cardiac stress, epilepsy, noise-induced hearing loss, or a combination thereof.

3 . A method for preventing, treating, and/or reducing the severity of a disease and/or condition associated with glutamate-induced excitotoxicity in a subject, the method comprising administering to said subject in need thereof a therapeutically effective amount of the neuroprotective compound according to any one of the following structures:

a pharmaceutically acceptable salt thereof.

4 . A method for effective prophylactic and management strategy to suppress neuronal death and cognitive impairment, the method comprising administering to said subject in need thereof a therapeutically effective amount of the neuroprotective compound according to any one of the following structures:

a pharmaceutically acceptable salt thereof.

5 . The method of claim 4 , wherein the diseases comprises Alzheimer's disease, cerebral ischemia, amyotrophic lateral sclerosis, traumatic brain injury, pen-operative neuronal and/or cardiac stress, epilepsy, noise-induced hearing loss, or a combination thereof.

6 . The method of claim 4 , wherein the condition comprises cognitive impairment, neurodegeneration, neuronal cell death, excitotoxic cell death, or a combination thereof.

7 . The method of any one of claims 1-6 , further comprising administering concurrently or subsequently a therapeutically effective amount of an open-channel N-methyl-Daspartate (NMDA) receptor blocker to the subject.

8 . The method of claim 7 , wherein the NMDA receptor blocker comprises memantine.